[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_97":98},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":40,"_57":40,"_58":59,"_60":61,"_62":63},"id","bmijsj6zc74jjfgl018hxqg92","revision",2,"title","Krystal Biotech 公布截至 9 月 30 日季度财务业绩","originalTitle","Krystal Biotech, Inc. (0001711279) (Filer)","summary","Krystal Biotech 于 11 月 2 日公布截至 9 月 30 日季度的财务业绩，并向 SEC 提交 Form 8-K。文件附有公司同日发布的新闻稿；正文未列出具体财务数据。","reason","source",{"_11":87,"_88":89,"_90":91,"_92":40,"_93":94,"_95":96},"links",{"_84":85,"_63":86},"publishedAt","2026-11-02T12:07:15.000Z","discoveredAt","2026-11-02T12:14:50.741Z","timelineAt","category","ai-products","tags",[82,83],"stockSymbols",[81],"score",26,"selected",true,"channel","news","story",{"_73":74,"_15":75},"x","readingMode","full","author","language","body",{"_77":-5,"_63":78,"_79":-5,"_80":61},"outline",[],"relatedStories",[76],"indexable","markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":72},"hasTranslation",false,"bodyLanguage","original","factId","fbyexDIHw63E",{"_73":74,"_15":75},"reportCount",3,"additionalSourceCount",1,"developmentCount",0,"publicId","fc2b14ba-ee27-4d3d-a1a2-81eca0c1e536","Krystal Biotech公布2026年第三季度业绩并启动最高4亿美元回购",{"_73":74,"_15":75},"zh","

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) November 2, 2026

KRYSTAL BIOTECH, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-38210

82-1080209

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(IRS Employer

Identification No.)

2100 Wharton Street, Suite 701

Pittsburgh, Pennsylvania 15203

(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code (412) 586-5830

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock

KRYS

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition

On November 2, 2026, Krystal Biotech, Inc., a Delaware corporation (the “Company”), announced its financial results for the quarter ending September 30, 2026. A copy of the Company’s press release is attached as Exhibit 99.1 hereto and incorporated by reference herein.

The information concerning financial results in this Form 8-K and in Exhibit 99.1 attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information concerning financial results in this Form 8-K and in Exhibit 99.1 attached hereto shall not be incorporated into any registration statement or other document filed with the Securities and Exchange Commission by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.


Exhibit No.		Description

99.1		Press Release, dated November 2, 2026
104		Cover Page Interactive Data file (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 2, 2026

KRYSTAL BIOTECH, INC.

By:

/s/ Krish S. Krishnan

Name:

Krish S. Krishnan

Title:

Chairman and Chief Executive Officer

","zhKind","complete","KRYS","公司与财报","财报","aihot","/items/bmijsj6zc74jjfgl018hxqg92","https://www.sec.gov/Archives/edgar/data/1711279/000171127926000072/0001711279-26-000072-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1794700800&sig=71ca7196cae6fb1a","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1794700800&sig=d7a6c96f6e081580 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1794700800&sig=32976cc557a9739a 96w","changelogVersion","2026-10-01T08:00"]